

Bipolar Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/BA11BF748933EN.html>

Date: May 2024

Pages: 140

Price: US\$ 6,499.00 (Single User License)

ID: BA11BF748933EN

Abstracts

The 7 major bipolar disorder markets reached a value of US\$ 3.1 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 3.8 Billion by 2034, exhibiting a growth rate (CAGR) of 1.82% during 2024-2034.

The bipolar disorder market has been comprehensively analyzed in IMARC's new report titled "Bipolar Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Bipolar disorder, also known as manic-depressive illness, refers to a mental health condition that causes extreme shifts in mood, energy, and activity levels. It can be classified into several types based on the pattern and severity of symptoms, including bipolar I, bipolar II, cyclothymic, and unspecified bipolar disorder. Individuals may experience episodes of mania or hypomania, during which they feel unusually elated, irritable, or energetic, and engage in impulsive or risky behaviors. They might also go through depressive periods where they feel sad and depressed and lose interest in things they used to enjoy. In some cases, people with bipolar disorder may exhibit psychotic indications like hallucinations or delusions. The diagnosis of the ailment is typically made by a mental health professional, such as a psychiatrist or psychologist, through a comprehensive assessment of the person's symptoms, medical history, and family history. This evaluation may include a physical exam, blood investigations, and psychological tests to rule out other conditions that may cause similar indications.

The increasing cases of neurochemical imbalances, which can cause symptoms of mania or depression, are primarily driving the bipolar disorder market. Furthermore, the rising prevalence of various associated risk factors, such as genetic predisposition, trauma, stress, substance abuse, etc., is also propelling the market growth. In addition

to this, the escalating utilization of antipsychotic medications, including olanzapine and risperidone, for managing manic episodes is creating a positive outlook for the market. Moreover, the inflating usage of cognitive-behavioral therapy (CBT) to assist patients in developing coping skills and identifying triggers for their symptoms, which can help them manage their condition more effectively, is also bolstering the market growth. Apart from this, the emerging popularity of electroconvulsive therapy, since it aids in lowering the indications of depression and mania in individuals with bipolar disorder, is acting as another significant growth-inducing factor. Additionally, the introduction of novel imaging technologies, such as functional magnetic resonance imaging (fMRI), for studying the brain and understanding the neural pathways associated with the ailment is expected to drive the bipolar disorder market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the bipolar disorder market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for bipolar disorder and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the bipolar disorder market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the bipolar disorder market
Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the bipolar disorder market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current bipolar disorder marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the bipolar disorder market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the bipolar disorder market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the bipolar disorder market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (?2018-2034?) of bipolar disorder across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of bipolar disorder by age across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of bipolar disorder by gender across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of bipolar disorder by type across the seven major markets?

How many patients are diagnosed (?2018-2034?) with bipolar disorder across the seven major markets?

What is the size of the bipolar disorder patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of bipolar disorder?

What will be the growth rate of patients across the seven major markets?

Bipolar Disorder: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for bipolar disorder drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the bipolar disorder market?

What are the key regulatory events related to the bipolar disorder market?

What is the structure of clinical trial landscape by status related to the bipolar disorder market?

What is the structure of clinical trial landscape by phase related to the bipolar disorder market?

What is the structure of clinical trial landscape by route of administration related to the bipolar disorder market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 BIPOLAR DISORDER - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (?2024-2034?)
- 4.4 Market Overview (2018-2023) and Forecast (?2024-2034?)
- 4.5 Competitive Intelligence

5 BIPOLAR DISORDER - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 BIPOLAR DISORDER - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (?2024-2034?)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Epidemiology by Type (?2018-2034?)
 - 7.2.6 Diagnosed Cases (?2018-2034?)
 - 7.2.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (?2024-2034?)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Epidemiology by Type (?2018-2034?)
 - 7.3.6 Diagnosed Cases (?2018-2034?)
 - 7.3.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (?2024-2034?)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Epidemiology by Type (?2018-2034?)
 - 7.4.6 Diagnosed Cases (?2018-2034?)
 - 7.4.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (?2024-2034?)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Epidemiology by Type (?2018-2034?)
 - 7.5.6 Diagnosed Cases (?2018-2034?)
 - 7.5.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (?2024-2034?)
 - 7.6.3 Epidemiology by Age (?2018-2034?)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Epidemiology by Type (?2018-2034?)
 - 7.6.6 Diagnosed Cases (?2018-2034?)

- 7.6.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (?2024-2034?)
 - 7.7.3 Epidemiology by Age (?2018-2034?)
 - 7.7.4 Epidemiology by Gender (?2018-2034?)
 - 7.7.5 Epidemiology by Type (?2018-2034?)
 - 7.7.6 Diagnosed Cases (?2018-2034?)
 - 7.7.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (?2024-2034?)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Epidemiology by Type (?2018-2034?)
 - 7.8.6 Diagnosed Cases (?2018-2034?)
 - 7.8.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (?2024-2034?)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Epidemiology by Type (?2018-2034?)
 - 7.9.6 Diagnosed Cases (?2018-2034?)
 - 7.9.7 Patient Pool/Treated Cases (?2018-2034?)

8 BIPOLAR DISORDER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 BIPOLAR DISORDER - UNMET NEEDS

10 BIPOLAR DISORDER - KEY ENDPOINTS OF TREATMENT

11 BIPOLAR DISORDER - MARKETED PRODUCTS

- 11.1 List of Bipolar Disorder Marketed Drugs Across the Top 7 Markets

11.1.1 Saphris (Asenapine) - AbbVie/ Lundbeck A/S/ Meiji Seika Pharma

- 11.1.1.1 Drug Overview
- 11.1.1.2 Mechanism of Action
- 11.1.1.3 Regulatory Status
- 11.1.1.4 Clinical Trial Results
- 11.1.1.5 Sales Across Major Markets

11.1.2 Vraylar (Cariprazine) - Gedeon Richter

- 11.1.2.1 Drug Overview
- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets

11.1.3 Zyprexa (Olanzapine) - Eli Lilly & Co.

- 11.1.3.1 Drug Overview
- 11.1.3.2 Mechanism of Action
- 11.1.3.3 Regulatory Status
- 11.1.3.4 Clinical Trial Results
- 11.1.3.5 Sales Across Major Markets

11.1.4 Seroquel (Quetiapine) - AstraZeneca

- 11.1.4.1 Drug Overview
- 11.1.4.2 Mechanism of Action
- 11.1.4.3 Regulatory Status
- 11.1.4.4 Clinical Trial Results
- 11.1.4.5 Sales Across Major Markets

11.1.5 Geodon (Ziprasidone) - Pfizer

- 11.1.5.1 Drug Overview
- 11.1.5.2 Mechanism of Action
- 11.1.5.3 Regulatory Status
- 11.1.5.4 Clinical Trial Results
- 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 BIPOLAR DISORDER - PIPELINE DRUGS

12.1 List of Bipolar Disorder Pipeline Drugs Across the Top 7 Markets

12.1.1 Brexpiprazole - Lundbeck/Otsuka

- 12.1.1.1 Drug Overview
- 12.1.1.2 Mechanism of Action

- 12.1.1.3 Clinical Trial Results
- 12.1.1.4 Safety and Efficacy
- 12.1.1.5 Regulatory Status
- 12.1.2 BXCL501 - BioXcel Therapeutics
 - 12.1.2.1 Drug Overview
 - 12.1.2.2 Mechanism of Action
 - 12.1.2.3 Clinical Trial Results
 - 12.1.2.4 Safety and Efficacy
 - 12.1.2.5 Regulatory Status
- 12.1.3 JNJ-55308942 - janssen-cilag
 - 12.1.3.1 Drug Overview
 - 12.1.3.2 Mechanism of Action
 - 12.1.3.3 Clinical Trial Results
 - 12.1.3.4 Safety and Efficacy
 - 12.1.3.5 Regulatory Status
- 12.1.4 Iloperidone - Vanda Pharmaceuticals
 - 12.1.4.1 Drug Overview
 - 12.1.4.2 Mechanism of Action
 - 12.1.4.3 Clinical Trial Results
 - 12.1.4.4 Safety and Efficacy
 - 12.1.4.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. BIPOLAR DISORDER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. BIPOLAR DISORDER – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 BIPOLAR DISORDER - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
 - 15.2.1 Bipolar Disorder - Market Size

- 15.2.1.1 Market Size (2018-2023)
- 15.2.1.2 Market Forecast (?2024-2034?)
- 15.2.2 Bipolar Disorder - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (?2024-2034?)
- 15.3 Market Scenario - United States
 - 15.3.1 Bipolar Disorder - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (?2024-2034?)
 - 15.3.2 Bipolar Disorder - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (?2024-2034?)
 - 15.3.3 Bipolar Disorder - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Bipolar Disorder - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (?2024-2034?)
 - 15.4.2 Bipolar Disorder - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (?2024-2034?)
 - 15.4.3 Bipolar Disorder - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Bipolar Disorder - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (?2024-2034?)
 - 15.5.2 Bipolar Disorder - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (?2024-2034?)
 - 15.5.3 Bipolar Disorder - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Bipolar Disorder - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (?2024-2034?)
 - 15.6.2 Bipolar Disorder - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (?2024-2034?)
 - 15.6.3 Bipolar Disorder - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Bipolar Disorder - Market Size

- 15.7.1.1 Market Size (2018-2023)
- 15.7.1.2 Market Forecast (?2024-2034?)
- 15.7.2 Bipolar Disorder - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (?2024-2034?)
- 15.7.3 Bipolar Disorder - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Bipolar Disorder - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (?2024-2034?)
 - 15.8.2 Bipolar Disorder - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (?2024-2034?)
 - 15.8.3 Bipolar Disorder - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Bipolar Disorder - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (?2024-2034?)
 - 15.9.2 Bipolar Disorder - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (?2024-2034?)
 - 15.9.3 Bipolar Disorder - Access and Reimbursement Overview

16 BIPOLAR DISORDER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 BIPOLAR DISORDER MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 BIPOLAR DISORDER MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Bipolar Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/BA11BF748933EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BA11BF748933EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

